VRNA Insider Trading Activity and SEC Form 4 Filings
VRNA insider trading summary
No open-market insider purchases or sales of Verona Pharma plc (VRNA) have been reported on SEC Form 4 in the past 12 months.
Latest VRNA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 1, 2025 | Andrew Fisher | General Counsel | Sell | $126K (9,584 @ $13.14) |
| Aug 1, 2025 | Christina Ackermann | Director | Sell | $24K (1,808 @ $13.14) |
| Aug 1, 2025 | Michael Austwick | Director | Sell | $148K (11,288 @ $13.14) |
| Aug 1, 2025 | David R Ebsworth | Director | Sell | $25K (1,904 @ $13.14) |
| Aug 1, 2025 | James Aloysius Brady | Director | Sell | $11K (824 @ $13.14) |
| Aug 1, 2025 | David Zaccardelli | President and CEO | Sell | $2.7M (208,912 @ $13.14) |
| Aug 1, 2025 | Martin Edwards | Director | Sell | $142K (10,808 @ $13.14) |
| Aug 1, 2025 | Vikas Sinha | Director | Sell | $57K (4,328 @ $13.14) |
| Aug 1, 2025 | Mahendra Shah | Director | Sell | $47K (3,608 @ $13.14) |
| Aug 1, 2025 | Mark W Hahn | Chief Financial Officer | Sell | $2.7M (208,912 @ $13.14) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.